Stratagene and Merck Subsidiary, Rosetta Inpharmatics, enter into joint development and license agreement
Development of RNA Purification System for Use in Molecular Diagnostics and Research Applications
16-Aug-2006
Under the terms of the agreement, Stratagene and Rosetta will jointly develop a proprietary instrument and a single-use consumable that will be manufactured and commercialized by Stratagene. These products will be sold to Stratagene's current customer base and companies engaged in pharmacogenomics. Financial terms of the agreement were not disclosed.
Most read news
Topics
Organizations
Merck Sharp & Dohme
Stratagene
Rosetta Inpharmatics
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.